GuruFocus.com

Durect Corp (DRRX) Files 10-K for the Fiscal Year Ended on December 31, 2018

GuruFocus.com

In This Article:

- By insider

Durect Corp (DRRX) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Durect Corp is a biopharmaceutical company. It develops pharmaceutical products based on two categories which include new chemical entities and drug delivery programs. The lead candidate for the company is DUR-928. Durect Corp has a market cap of $111.820 million; its shares were traded at around $0.69 with and P/S ratio of 3.11.


For the last quarter Durect Corp reported a revenue of $8.04 million, compared with the revenue of $20.75 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $18.6 million, a decrease of 62.2% from the previous year. For the last five years Durect Corp had an average revenue growth rate of 10.3% a year.

The reported loss per diluted share was 16 cents for the year, compared with the loss per share of $0.19 in the previous year. The Durect Corp had an operating margin of -127.23%, compared with the operating margin of -4.55% a year before. The 10-year historical median operating margin of Durect Corp is -108.14%. The profitability rank of the company is 2 (out of 10).

At the end of the fiscal year, Durect Corp has the cash and cash equivalents of $31.6 million, compared with $29.4 million in the previous year. The long term debt was $20.5 million, compared with $12.6 million in the previous year. Durect Corp has a financial strength rank of 4 (out of 10).

At the current stock price of $0.69, Durect Corp is traded at 62.1% discount to its historical median P/S valuation band of $1.82. The P/S ratio of the stock is 3.11, while the historical median P/S ratio is 8.08. The stock lost 61.49% during the past 12 months.

For the complete 20-year historical financial data of DRRX, click here.

This article first appeared on GuruFocus.


and

Recommended Stories